Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Nevertheless, over the last twenty years there has been an increasing number of clinical studies evaluating nose-to-brain delivery as a novel option for the treatment of neurodegenerative and neurological diseases
After all, we are talking about your health
(2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Would you like to explore what tailored treatment package might work for you
The agency is expected to release its verdict on the drug in the fourth quarter of this year
US$ 25.90
US$ 20.48
US$ 20.78
US$ 26.57
